USPTO Cancer Moonshot Challenge – Our Visualization Story

The best visualizations transfer knowledge not just to individuals but to groups, building consensus. We demonstrate a recent Melanoma Landscape in Intellar,^M a friendly horizon scanning tool. Intellar builds a more complete picture for users having varied levels of expertise. It enables collaboration by linking big data visualizations from "high level pictures" to "deep dives" so users reach funding and policy decisions together.

Melanoma Focus

According to cancerresearch.org, melanoma is the most aggressive and deadliest form of skin cancer. In 2016 in the U.S. ~76,380 new melanomas will be diagnosed, and ~10,130 people will die. A substantial unmet need still remains for new therapies.


According to the Orange Book/Purple Book, 8 new melanoma drugs/therapies are FDA approved since 2011. There are 4 immunotherapies: Ipilimumab (Yervoy®); Pembrolizumab (Keytruda®); Nivolumab (Opdivo®); Talimogene laherparepvec (T-VEC, ImlygicTM). The first three are checkpoint inhibitors that "take the brakes off" the immune system; the last is an oncolytic virus therapy. There are also 4 targeted therapies: Vemurafenib (Zelboraf®); Dabrafenib (Tafinlar®); Trametinib (Mekinist®); Cobimetinib (Cotellic®). These target common genetic mutations, e.g., BRAFV600 mutation.

The Dataset

This landscape covers publishing since 2000 in melanoma to demonstrate insights in one commercial therapeutic area.

- 264 US patents and 983 applications (from USPTO Developer data accessed on Thomson Innovation; de-duped to latest non-expired member of DWPI family) related to melanoma, and/or breakthrough therapy terms
- 1,346 Literature items covering actual research (journals, clinical trials, studies; not editorial/opinion) from ISSN's with 10+ relevant hits in EBSCO Medline
- 408 News items from EBSCO Business Source Corporate Plus, Newswires and Web News
- Technology thesaurus to categorize records into a taxonomy of 6 areas and 46 therapeutic categories
- Events thesaurus to categorize records in 10 areas and 91 commercial categories
- Data organized in Vantage Point 9.0 from Search Technology before import to Intellar

Organizations Active in Melanoma




Roll over the executive summary block at the top of the Organizations View (or any other View) to see the full landscape summary.

P Organizations USPTO C ×			
← → C ▲ https://intellar.com/Demo2/orgtile/view/213			☆ 🖸 :
USPTO Cancer Moonshot Ch Melanoma Landscape Patents, Applications, Literature & News sin	-	Update Overview The goal of this project is to enable better funding the second secon	Intellant Control of C
Landscape Organizations OrgTypes Categories	Records	Ŧ 🗅	Filter this Organizations view
Reported Sep 19, 2016 😡 Big Pharma #2 Organization 🌾 5 In this report by items (200)	Reported Sep 19, 2016 🨡	Big Pharma #3 Organization this report by items (174)	(640 Organization Tiles with 1+ • records) C And ±
Bristol-Myers Squibb		Genentech	▼ Filter 640 / 640 Tiles
Bristol-Myess Spatible 2 2014 2014 2014 2014 2014 2014 2014 20	Genentech	56 13 0	Start 01/01/2000 End 09/01/2016 Date Publication ▼ Votes ம
So Most Active Categories ± Reported Sep 1% 2016 So Government #1 Organization ⊯ 0	Most Active C	ategories ≰ Big Pharma #4 Organization ⊮ o	Sort by If Number of Records per Organization If Latest Publication Date If Organization Name IF Votes
in this report by items (337) 🌼 0	Neponed Sep 19, 2016 SQ	in this report by items (133) 🏼 🎼 0	Organizations If
US Food & Drug Administration	A	²⁹ Merck	► OrgTypes 11
00 2004 2008 2016 By Year	MERCK	14 0 2006 2004 2006 2016 By Year	People 1 Locations 1
* Most Active Categories ±	🐞 Most Active C	<u>*</u>	Events If Area If Category Commenters If Categories If Area If Category
Reported Sep 19, 2016 😡 Oovernment #5 Organization 🔖 0 in this report by Items (116)	Reported Sep 19, 2016 🧖	Publisher #6 Organization 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
US DHHS	America	n Association for Cancer	
و Patent کې د SB0020 کې د د او ک		Pasaarah	


In this landscape there are 640 unique organizations/publishers. Organizations are displayed in tiles (un/collapsed by arrow icons) and are filterable/sortable by attributes in the collapsing right pane. Bar charts depict publishing by Document Type by Organization by Year. It is evident for

firms that most of the time, patenting (green and gold data series) precedes other publications (violet & orange). This reinforces the value of patents (and USPTO) as an early indicator in Melanoma research.



By expanding Organization tiles one can compare details between firms. Above, we see (across the innovation area pie charts; top category bottom boxes; categories in right pane and TFIDF extracted concepts) the research differences between BMS – with more US research efforts directed more to antibodies – compared to Genentech with more small molecule approaches targeted to B-RAF. User comments in context can hide/show at top of tiles (balloon icons). Voted tiles sort in right pane to make this comparison.

Organization Types



This collapsed Organization Types View reveals meaningful publishing trends. Looking carefully one sees the earliest publishing is in USPTO patents/applications (green/gold), demonstrating incentives to patent first in almost every Organization Type. To improve early investment, one would need to monitor Government publications (purple) or hone in on news (orange) about e.g., business events involving Life Sciences Companies. As Publisher output picks up in the Landscape, earlier studies are often not reported by highest-impact journals until approved by the FDA. This indicates a need for smarter library subscription policies to obtain lower-impact journals that may not be in "popular" collections, but which could provide more bang for the buck, if focused on Melanoma.

Melanoma Taxonomies

Intella How's everyone doing	USPTO Cancer Melanoma Lano Patents, Applications, L	Moonshot C dscape iterature & News si	hallenge		project is to enable better fundir s & literature & news in Melanom	a published 2000 - 2016	ered by
Landscape Oi	rganizations OrgTypes	Categories	Records			Filter this Categories view	٦
S Approved Drugs	Show Bar Graphs Foatures 6 60 Cost-effective 152 High Selectivity 153 Low Side effect 255 Potent 228 Synergistic 474 Targeted Treatment	Molecular Targets	Areas & Categories	Targeted Metastasis Organs 54 Bone 109 Brain 4 Gi Tract 1 6 Kidney 63 Liver 116 Lung 89 Lymph Node 1 1 Spleen	Therapeutic Options	C Add • Yeare • Learent • Learent • Organizations II 263/7 US Food & Drug, 263/7 Bristob-Myers, 6/7/75/32 Genentech 16/7/57/25 Marcian A 9 Novaria 6/37/163 • Categories If Area Tstages/Primary Tumor 263 Tstages/Primary Tumor	s 8 8 4 0 0 ↓ 2 4 4 7 0 0

The Categories View shows a technology taxonomy emphasizing activity by Document Type. Important areas are Approved Drugs, Molecular Targets and Therapeutic Options. B-RAF, and CTLA-4 Receptors are the most popular targets in the literature. PI3K-AKT is the most patented to date for Melanoma.

Intellar How's everyone doing?	USPTO Cancer Melanoma Land Patents, Applications, Li	lscape			project is to enable better fundir s & literature & news in Melanon	na published 2000 - 2016
Landscape Org	ganizations OrgTypes		Records Areas & Categories			Filter this Categories view
Approved Drugs	Cost-effective Cost-effective High Selectivity Cost-effect Cost-e	Molecular Targets 14 B-RAF 9 CTLA-4 4 Fas Receptor 1 MAGEA1 8 MAPK or MEK 1 1 MITF 1 PARP 20 PJKS-AKT 1 PMEL 1	Stages 67 Metastasis 111 Primary Tumor 38 Tumor-initiating	Targeted Metastasis Organs 2 Bone 1 Gi Tract 1 3 Liver 1 7 Lung 8 Lymph Node	Therapeutic Options 40 Antbody 37 Gene Therapy - General 11 Interferon 15 Interfeukin 1 MicroRNA I 2 Oncolytic Virus I 70 Small Molecule 12 Surgical Excision 21 Vaccine - General	• Patter • Applications 11 US Food & Drug

Filtering on the right pane shows taxonomy co-occurrence by any number of Organizations or Categories. Here we see the "weight" of Melanoma patents and literature funded by US DHHS.

https://intellar.com/Demo: https://intellar.com/Demo: https://intellar.com/Demo: how's everyone doing?	USPTO Cancer I Melanoma Land	Moonshot Challenge scape erature & News since 2000	Update Overview The goal of this project is to enable better fund It covers patents & literature & news in Melanon It covers and the set of th	
Landscape Orga	nizations OrgTypes	Categories Records		Filter this Categories view
S 9 4 0 1	all	S Event Areas & Categories		C And ±
Collaborations	• •	gal Events Marketing Events	Milestones People Events	Patent Application Utrature News Organizations I1 US Food & Drug 263/74
1 Alliance	86 Acquisition	3 Appeal - 15 Conference	- 302 Adverse - 4 Chosen	Bristol-Myers 6/17/52/125
5 Co-development	15 Agreement	1 Contract 2 Forum	43 Anniversary 1 Engaged	Genentech 15/59/42/58 Merck 6/46/13/68
15 Collaboration	8 Deal	50 Corrected - 1 Gathering	301 Approved 21 Takes Position	US DHHS 46/60/6/4 American A 90 Novartis 6/37/15/30 -
2 Initiative	3 Disposition	1 Dispute 17 Marketing	4 Award	
1 Joint Venture	1 Earnings	1 Infringement 5 Online Presence	- 31 Failure	Stages/Primary Tumor 2680 Therapeuti/Small Mole 1702 Stages/Metastasis 1544
15 Partner	2 Expenditure	15 License 1 Promotion	1 First Ever	Therapeuti/Antibody 1297 Stages/Tumor-init 1210
	3 Funded	23 Likely Expired 1 Sessions	— 17 Milestone	Molecular/B-RAF 940 Molecular/CTLA-4 791 -
	4 Funding	99 Mediation 3 Sponsorship	2 Prize	
	9 Grant	167 More than 20 3 Workshop Forward Citations	- 31 Recognition	
	3 Investment	52 More than 20 Ind	68 Success	
	45 Loss	Claims I	2 Turning Point	
	2 Negotiation	724 More than 20 INPADOC Family	- 1 Victory	

Selecting the blue dollar sign in the upper left corner reveals the Events taxonomy. Here we can see the intensity of commercial activity and indicators for opportunities & risks.

Melanoma Landscape

In	s://intellar.com/Demu tellar everyone doing?	USPTO C Melanom	na Landsc	ape	not Challenge		project is to enable better funding & s & literature & news in Melanoma p		
Land	scape Orga	anizations O	orgTypes C	Catego	ries Records			Filter this Landscape view	
	1	2	3	4	Approved Drugs	5 Features	Molecular Targets	The the canabape field	. 1
	ntity of Patents ations & Literature Patera Applications Literature News	Presumed Assignee Name	Percent of Patent Portfolio by Publication Year (2000 - 2016)	Percent Recently Filed (2013 - 2016)	Imitygie Kariuda Kervus Opdino Opdino Zelboorg Zelboorg	Cost effective High Selectivity Low Side effect Potent Symergistic Targeted Treatment	Denota CTLA-4 Fas Receptor MARF on MEK MAPF on MEK PARP PARP DD-1 Receptor	C or 2 • Paier • Application • Lineater • here • Organizations II US Food & Drug • 6/17/82/125 Genentech • 15/59/42/258 Mercik • 6/46/13/68 US DHHS • 46/60/6/4 American A • 90	
	0/0/263/74 6/17/52/125	US Food & Drug Bristol-Myers	2000	63% 64%			ь^	Novartis 6/37/15/30 - Categories là Area II Category Therapeuti/Antibody 1297 Therapeuti/Gene Thera 408	
	15/59/42/58	Genentech	An	43%				Therapeuti/Interferon 85	
	6/46/13/68	Merck		61%			pats: 12, apps: 19, lits: 42, news: 55	Therapeuti/Interleukin 117 Therapeuti/MicroRNA 4	
	46/60/6/4	US DHHS	hand	17%				Therapeuti/Oncolytic 84 Therapeuti/Small Mole 1702 *	
	0/0/90/0	American Assoc.		79%					1
	6/37/15/30	Novartis	and	43%					1
	0/0/69/4	American Socie		51%					
	4/56/2/7	Pfizer	man	13%					
	0/0/66/0	Clin Cancer Res	M	59%					- 1


The Landscape map shows all Organizations (rows) by all technology Categories (columns) by all Document Types (cells).

Quantity of Patents Applications & Literature Memory Presumed Assignee Name Percent of Patent Potholic by Publication Vear (2009 - 2016) Percent of Patent Potholic by Publication Vear (2009 - 2016) Percent of Patent Potholic by Publication Potholic Patent Potholic by Publication Potholic Patent Potholic by Publication Potholic Patent Potholic Barsol Percent of Patent Potholic Patent Patent Potholic Patent Patent Potholic Patent Potholic Patent Patent Potholic Patent	view C or ± • News
1 2 3 4 5 Quantity of Patents Applications & Literature base Presumed Assignee Name Percent of Patent by Publication Vear (coole - Jointo) Percent of Patent Vear (coole - Jointo) Percent of Paten	C or ±
Quantity of Patents Applications & Literature bieren Presumed Assignee Name Percent of Patent Potholic by Publication Vear (2000 - 2016) Percent of Patent Potholic by Publication Polic (1002 - 1000) Percent of Patent Potholic by Publication Polic (1002 - 1000) Percent of Patent Polic (1002 - 1000) Percent of Patent Polic (1002 - 1000) Percent of Polic (1002 - 1000)<	
• Categories B Ares II Categor	263/74 /17/52/125 5/59/42/58 6/46/13/68 46/60/6/4 90
6/17/52/125 Bristol-Myers 64% 64%	85 * 117
15/99/42/58 Genentech 43% 43% C Therapeuti/MicroRNA C Therapeuti/MicroRNA	4 84
6/46/13/68 Merck 61% 61% C Therapeuti/Small Mole C Therapeuti/Surgical E	92
46/60/6/4 US DHHS 17% Therapeuti/Vaccine	334 -
0/0/99/0 American Assoc.	
43% 43% 43% 43%	
4/56/2/7 Pfizer 13%	


Right pane filters customize the map. Publishing trends reveal organizational strategies. Most focus on Antibodies, while e.g., Amgen is focused on Oncolytic Virus. More Government

investment may be necessary here. Note that FDA, DHHS, and American Assc. for Cancer Research appear to have invested primarily outside of Oncolytic therapies to date.

Record Observations



Right-clicking on any Landscape intersection (or Records View in menu) will drill down into documents for key Organizations and Categories. Titles link to open source record versions; publication numbers link to deep web versions. The Excel icon in the top right pane downloads visible records and metadata.



Records may be expanded from the top nav bar and filtered by any category or attribute in the right pane.

ories USPTO Canic 🗴 👔 Landscape USPTO Canic 🗴 🧗 Records USPTO Cancer 🗴		ا الفا الع
https://intellar.com/Demo2/records/view/213		Ŕ
USPTO Cancer Moonshot C Melanoma Landscape Patents, Applications, Literature & News si	The goal of this project is to enable better funding & point	
Landscape Organizations OrgTypes Categories	Records 2	Filter this Record Tile view
e Beported Sep 19, 2016 New 0. System User Sep 12, 2016 ¥ 0. System User Sep 12, 2016 ¥ 0. System User Sep 12, 2016 ¥	Breartel Sep 13 2016 US20150202290A1 Application O System User Sep 18 2016 X O System User Sep 18 2016 X O Filed by Angen for Talimogene laherpareprec (T-VEC, Inlygic)	
Antibodies to human programmed death receptor PD-1	Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor	Start 01/01/2000 End 09/01/2016 Date Publication • Votes 10 p • Patent • Application • Literature • News
Assignee Merck Inventor Carven Gregory John Dulos Gradus Johannes Van Eenennaam Hans Published Dec 02, 2014 Priority Jun 18, 2007 Jun 13, 2008 Jun 21, 2010	Assigne Amgen Inventor Shabooti Mohamed Vanderwalde Ari Vanderwalde Ari Published Jul 23, 2015 Priority Aug 30, 2013 Aug 30, 2013	Sort by If Publication Date If Author If Author If Publication Number If Title If Votes Organizations II OrgTypes II
Antibodies which block binding of hPD-1 to hPD-11 or hPD-12 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.	simplex virus in combination with an immune checkpoint inhibitor. Active Categories Stages/Primary T Stages/Metastasis Therapeutic/Antibody	People If Locations If Events If Area If Category Commenters If
♦ Active Categories \$tages/Primary T Therapeutic/Antibody Molecular Ta/CTLA-4 Molecular Ta/PD-1 Rece Features/Low Side Approved Drugs/Keytruda	Approved Drugs/Opdivo Approved Drugs/Keytruda Therapeutic/Surgical Therapeutic/Oncolytic Approved Drugs/Imlygic	None 2982 All 19 System User 19 Categories System User
O Active Events	Legal Events/Triadic Legal Events/Reassignment	• Records 11

Filtering by commenter highlights patents with expert (or algorithmic) conversations in context.

Conclusion

Intellar's linked visualizations reveal new opportunities for Melanoma funding and policy. Government and researcher users learn how to better direct/request funding to less-active but promising technologies (e.g., Oncolytics). Policy makers can identify journals more likely to publish early research in Melanoma, optimizing subscriptions in research libraries. Finally, as patents remain the earliest indicators in Melanoma, scientists and patent examiners can set up periodic monitoring to systematically discover emergent art and debate the significance in context.


In the near future Intellar will import social and financial data as well.

USPTO Cancer Moonshot Challenge – Testing Instructions

Accessing this information online requires the following login:

Login:	https://intellar.com/Demo2/welcome
User ID:	demo2intellar@perceptionpartners.com
PW:	intellarwins1

Chrome or Firefox is strongly recommended to review this submission. Please bookmark this submission to return to it.



There is a help link in the upper right after login.



The Help link contains marked up screenshots and release notes.



We can also be reached for rapid support by clicking the Contact link, also in the upper right.